| Name | Letrozole |
| Classes |
Anticancer/Antineoplastic Agent |
| Diseases |
Breast Cancer Cancer |
Bangla
EnglishLetrozole
Letrozole is a nonsteroidal competitive inhibitor of the aromatase enzyme system; it inhibits the conversion of androgens to estrogens. Estrogens stimulate or maintain the growth of some breast cancers. Treatment of hormonally responsive breast cancer (i.e., estrogen and/or progesterone receptor positive or receptor unknown) has included a variety of efforts to reduce estrogen levels (ovariectomy, adrenalectomy, hypophysectomy) or inhibit estrogen effects (antiestrogens and progestational agents). In some women, these interventions result in a decrease in tumor mass or a delay in tumor progression.
Letrozole is an aromatase inhibitor indicated for:
- Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer
- Extended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy
- First and second-line treatment of postmenopausal women with hormone receptor positive or unknown advanced breast cancer
- Letrozole tablets are taken orally without regard to meals
- Recommended dose: 2.5.mg once daily
- Patients with cirrhosis or severe hepatic impairment: 2.5 mg every other day
- Decreases in bone mineral density may occur. Consider bone mineral density monitoring
- Increases in total cholesterol may occur. Consider cholesterol monitoring.
- Fatigue, dizziness and somnolence may occur. Exercise caution when operating machinery
Contraindication
Contraindicated in patients hypersensitive to letrozole.
None known.
Letrozole is contraindicated in-
- Women of premenopausal endocrine status
- pregnant women